Your browser doesn't support javascript.
Advances and gaps in SARS-CoV-2 infection models.
Muñoz-Fontela, César; Widerspick, Lina; Albrecht, Randy A; Beer, Martin; Carroll, Miles W; de Wit, Emmie; Diamond, Michael S; Dowling, William E; Funnell, Simon G P; García-Sastre, Adolfo; Gerhards, Nora M; de Jong, Rineke; Munster, Vincent J; Neyts, Johan; Perlman, Stanley; Reed, Douglas S; Richt, Juergen A; Riveros-Balta, Ximena; Roy, Chad J; Salguero, Francisco J; Schotsaert, Michael; Schwartz, Lauren M; Seder, Robert A; Segalés, Joaquim; Vasan, Seshadri S; Henao-Restrepo, Ana María; Barouch, Dan H.
  • Muñoz-Fontela C; Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
  • Widerspick L; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.
  • Albrecht RA; Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
  • Beer M; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.
  • Carroll MW; Department of Microbiology, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
  • de Wit E; Friedrich-Loeffler-Institut, Institute of Diagnostic Virology, Greifswald-Insel Riems, Germany.
  • Diamond MS; National Infection Service, Public Health England, Salisbury, United Kingdom.
  • Dowling WE; Pandemic Sciences Centre, Nuffield Department of Medicine, Oxford University, United Kingdom.
  • Funnell SGP; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.
  • García-Sastre A; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
  • Gerhards NM; Coalition for Epidemic Preparedness Innovations (CEPI), Washington, Washington, DC, United States of America.
  • de Jong R; National Infection Service, Public Health England, Salisbury, United Kingdom.
  • Munster VJ; Department of Microbiology, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
  • Neyts J; Wageningen Bioveterinary Research, Lelystad, the Netherlands.
  • Perlman S; Wageningen Bioveterinary Research, Lelystad, the Netherlands.
  • Reed DS; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.
  • Richt JA; KU Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium.
  • Riveros-Balta X; Department of Microbiology and Immunology, University of Iowa, Iowa City, Iowa, United States of America.
  • Roy CJ; Center for Vaccine Research and Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
  • Salguero FJ; Kansas State University, College of Veterinary Medicine, Manhattan, Kansas, United States of America.
  • Schotsaert M; World Health Organization, Geneva, Switzerland.
  • Schwartz LM; Tulane National Primate Research Center, Covington, Louisiana, United States of America.
  • Seder RA; National Infection Service, Public Health England, Salisbury, United Kingdom.
  • Segalés J; Department of Microbiology, Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
  • Vasan SS; World Health Organization, Geneva, Switzerland.
  • Henao-Restrepo AM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Barouch DH; Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus UAB, and Departament de Sanitat i Anatomia animals, Facultat de Veterinària, UAB, Barcelona, Spain.
PLoS Pathog ; 18(1): e1010161, 2022 01.
Article in English | MEDLINE | ID: covidwho-1703195
ABSTRACT
The global response to Coronavirus Disease 2019 (COVID-19) is now facing new challenges such as vaccine inequity and the emergence of SARS-CoV-2 variants of concern (VOCs). Preclinical models of disease, in particular animal models, are essential to investigate VOC pathogenesis, vaccine correlates of protection and postexposure therapies. Here, we provide an update from the World Health Organization (WHO) COVID-19 modeling expert group (WHO-COM) assembled by WHO, regarding advances in preclinical models. In particular, we discuss how animal model research is playing a key role to evaluate VOC virulence, transmission and immune escape, and how animal models are being refined to recapitulate COVID-19 demographic variables such as comorbidities and age.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Disease Models, Animal / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: PLoS Pathog Year: 2022 Document Type: Article Affiliation country: Journal.ppat.1010161

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Disease Models, Animal / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: PLoS Pathog Year: 2022 Document Type: Article Affiliation country: Journal.ppat.1010161